Authors: | Wood, L. S.; Lemont, H.; Jatoi, A.; Lacouture, M. E.; Robert, C.; Keating, K.; Anderson, R. |
Article Title: | Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors |
Abstract: | Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR. © 2010 Elsevier Inc. All rights reserved. |
Keywords: | cancer chemotherapy; debridement; unclassified drug; clinical feature; clinical trial; disease course; sorafenib; bevacizumab; doxorubicin; fluorouracil; sunitinib; treatment duration; hand foot skin reaction; skin manifestation; capecitabine; cancer patient; disease association; peripheral neuropathy; hyperkeratosis; drug hypersensitivity; disease severity; prophylaxis; cediranib; pazopanib; erythema; rating scale; daily life activity; emollient agent; dermatitis; lidocaine; axitinib; disease control; hand foot syndrome; hypersensitivity reaction; analgesic agent; pyoderma gangrenosum; lactic acid; self care; fluocinonide; tazarotene; urea; blister; salicylic acid; skin edema; skin pain; votrient; skin abrasion; 2 hydroxyacid; cerave; clobetasol propionate; glycolic acid; keratolytic agent; lanolin alcohol; petrolatum; pumice; callus; cream; metatarsal bone |
Journal Title: | Community Oncology |
Volume: | 7 |
Issue: | 1 |
ISSN: | 1548-5315 |
Publisher: | Elsevier Inc. |
Date Published: | 2010-01-01 |
Start Page: | 23 |
End Page: | 29 |
Language: | English |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "Source: Scopus" |